Clinical and immunological characteristics | N = 2051 | P value* |
---|---|---|
Clinical Characteristics | ||
WHO Clinical stage | < 0.01 | |
Stage 1 | 40 (20) | |
Stage 2 | 54 (26) | |
Stage 3 | 90 (44) | |
Stage 4 | 21 (10) | |
Type of ARV treatment | < 0.01 | |
First line | 167 (81) | |
Second line | 38 (19) | |
Duration of treatment (in years) | < 0.01 | |
0–4 | 52 (25) | |
5–9 | 85 (41) | |
10–14 | 46 (22) | |
≥ 15 | 22 (11) | |
Immunological Characteristics | ||
CD4 T-cell count (Cellules/mm3) | < 0.01 | |
< 200 | 21(10) | |
200–500 | 154 (75) | |
≥ 500 | 30 (15) |